Ridhima Wadhwa

Ridhima Wadhwa

Auto-generated profile, based on publicly available information

Ridhima Wadhwa

Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences , Sydney, New South Wales

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2020 in Journal of Food Biochemistry
Verified
Journal Article
Closed access
PDF file
RWRidhima Wadhwa
Ridhima Wadhwa
Keshav Raj PaudelKeshav Raj Paudel
Keshav Raj Paudel
LCLi Hian Chin
Li Hian Chin
CHChian Ming Hon
Chian Ming Hon
TMThiagarajan Madheswaran
Thiagarajan Madheswaran
Kamal DuaKamal Dua
Kamal Dua

2 December 2020 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
TATaru Aggarwal
Taru Aggarwal
RWRidhima Wadhwa
Ridhima Wadhwa
RGRiya Gupta
Riya Gupta
Keshav Raj PaudelKeshav Raj Paudel
Keshav Raj Paudel
Trudi ColletTrudi Collet
Trudi Collet
Pawan MauryaPawan Maurya
Pawan Maurya
Regardless of advances in detection and treatment, breast cancer affects about 1.5 million women all over the world. Since the last decade, genome-wide association studies (GWAS) have been extensively conducted for breast cancer to define the role of miRNA as a tool for diagnosis, prognosis and therapeutics. MicroRNAs are small, non-coding RNAs that are associated with the regulation of key cellular processes such as cell multiplication, differentiation, and death. They cause a disturbance in the cell physiology by interfering directly with the translation and stability of a targeted gene transcript. MicroRNAs (miRNAs) constitute a large family of non-coding RNAs, which regulate target gene expression and protein levels that affect several human diseases and are suggested as the novel markers or therapeutic targets, including breast cancer. MicroRNA (miRNA) alterations are not only associated with metastasis, tumor genesis but also used as biomarkers for breast cancer diagnosis or prognosis. These are explained in detail in the following review. This review will also provide an impetus to study the role of microRNAs in breast cancer.

21 April 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
LFLauren H. Fairley
Lauren H. Fairley
SDShatarupa Das
Shatarupa Das
Vivek DharwalVivek Dharwal
Vivek Dharwal
NANadia M Lopes Amorim
Nadia M Lopes Amorim
KHKarl J. Hegarty
Karl J. Hegarty
PHPhilip M. Hansbro
Philip M. Hansbro
Oxidative stress is a major hallmark of COPD, contributing to inflammatory signaling, corticosteroid resistance, DNA damage, and accelerated lung aging and cellular senescence. Evidence suggests that oxidative damage is not solely due to exogenous exposure to inhaled irritants, but also endogenous sources of oxidants in the form of reactive oxygen species (ROS). Mitochondria, the major producers of ROS, exhibit impaired structure and function in COPD, resulting in reduced oxidative capacity and excessive ROS production. Antioxidants have been shown to protect against ROS-induced oxidative damage in COPD, by reducing ROS levels, reducing inflammation, and protecting against the development of emphysema. However, currently available antioxidants are not routinely used in the management of COPD, suggesting the need for more effective antioxidant agents. In recent years, a number of mitochondria-targeted antioxidant (MTA) compounds have been developed that are capable of crossing the mitochondria lipid bilayer, offering a more targeted approach to reducing ROS at its source. In particular, MTAs have been shown to illicit greater protective effects compared to non-targeted, cellular antioxidants by further reducing apoptosis and offering greater protection against mtDNA damage, suggesting they are promising therapeutic agents for the treatment of COPD. Here, we review evidence for the therapeutic potential of MTAs as a treatment for chronic lung disease and discuss current challenges and future directions.

25 March 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
RWRidhima Wadhwa
Ridhima Wadhwa
TATaru Aggarwal
Taru Aggarwal
VMVamshikrishna Malyla
Vamshikrishna Malyla
NKNitesh Kumar
Nitesh Kumar
GGGaurav Gupta
Gaurav Gupta
Kamal DuaKamal Dua
Kamal Dua

22 November 2023 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MYMaureen Yin
Maureen Yin
RWRidhima Wadhwa
Ridhima Wadhwa
JMJacqueline E Marshall
Jacqueline E Marshall
CGCaitlin M. Gillis
Caitlin M. Gillis
RKRichard Y. Kim
Richard Y. Kim
Luke O'NeillLuke O'Neill
Luke O'Neill
4-Octyl itaconate (4-OI) is a derivative of the Krebs cycle–derived metabolite itaconate and displays an array of antimicrobial and anti-inflammatory properties through modifying cysteine residues within protein targets. We have found that 4-OI significantly reduces the production of eosinophil-targeted chemokines in a variety of cell types, including M1 and M2 macrophages, Th2 cells, and A549 respiratory epithelial cells. Notably, the suppression of these chemokines in M1 macrophages was found to be NRF2-dependent. In addition, 4-OI can interfere with IL-5 signaling and directly affect eosinophil differentiation. In a model of eosinophilic airway inflammation in BALB/c mice, 4-OI alleviated airway resistance and reduced eosinophil recruitment to the lungs. Our findings suggest that itaconate derivatives could be promising therapeutic agents for the treatment of eosinophilic asthma.

12 December 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
MMMeenu Mehta
Meenu Mehta
Daljeet DhanjalDaljeet Dhanjal
Daljeet Dhanjal
SSSaurabh Satija
Saurabh Satija
RWRidhima Wadhwa
Ridhima Wadhwa
Keshav Raj PaudelKeshav Raj Paudel
Keshav Raj Paudel
Kamal DuaKamal Dua
Kamal Dua
Cell Signaling pathways form an integral part of our existence, that allows the cells to comprehend a stimulus and respond back. Such reactions, to external cues from the environment, are required and are essential to regulate the normal functioning of our body. Abnormalities in the system arise when there are errors developed in these signals, resulting in a complication or a disease. Presently, respiratory diseases contribute to being the third leading cause of morbidity worldwide. According to the current statistics, over 339 million people who are asthmatic, 65 million who are suffering from COPD, 2.3 million who are lung cancer patients and 10 million are tuberculosis patients. This toll of statistics with chronic respiratory diseases leaves a heavy burden on society and nation annual health expenditure. Hence, a better understanding of the processes governing these cellular pathways will enable us to treat and manage these deadly respiratory diseases effectively. Moreover, it is important to comprehend the synergy and interplay of the cellular signaling pathways in respiratory diseases, which will enable us to explore and develop suitable strategies for targeted drug delivery. This review, in particular, focuses on the major respiratory diseases and further provides an in-depth discussion on the various cell signaling pathways that are involved in the pathophysiology of respiratory diseases. Moreover, the review also analyses the defining concepts about advanced nano-drug delivery systems involving various nanocarriers and propose newer prospects to minimize the current challenges faced by researchers and formulation scientists.